IP Library Granted Patent US 11,491,104
Granted Patent B2
US 11,491,104 · App. 17/064,327 · Granted Nov 8, 2022

Compositions and uses of alpha-adrenergic agents

Inventors: Frank Litvack (Los Angeles, CA); Houman Hemmati (Los Angeles, CA)
Assignee: LEVATION PHARMA LTD.
A61K9/0014A61K8/4946A61K9/0019A61K9/0048A61K31/4174A61P21/00A61P27/02A61Q1/10A61Q19/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,491,104
App. No.
17/064,327
Granted
Nov 8, 2022
Kind
B2
Abstract

The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disclosure may be used cosmetically to improve the appearance of the eye or therapeutically to treat ptosis.

Claims (20)

1. A cosmetic gel composition for the eyelid comprising an alpha-adrenergic agent and a permeation enhancer,

wherein a dose of the cosmetic gel composition comprises from about 0.5 mg to 8 mg of the alpha-adrenergic agent

wherein the alpha-adrenergic agent is oxymetazoline or a salt thereof,

wherein the permeation enhancer is less than 40% by weight of the total composition, and

wherein the cosmetic gel composition comprises one or more cosmetic excipients.

2. The cosmetic gel composition of claim 1 , wherein the dose of the cosmetic gel composition comprises from about 3 to 6 mg of oxymetazoline or a salt thereof.

3. The cosmetic gel composition of claim 1 , wherein the permeation enhancer is less than 30% by weight of the total composition.

4. The cosmetic gel composition of claim 1 , wherein the permeation enhancer is less than 20% by weight of the total composition.

5. The cosmetic gel composition of claim 1 , wherein the permeation enhancer is selected from ethanol, propylene glycol, dodecyl-N,N-dimethyl-aminoacetate, ethylacetate, azone, sodium dodecyl sulfate, d-limonene, oleic acid, 1,3-diphenyl-urea, N-methyl-2-pyrrolidone, beta-cyclodextrin, and dimethylsulfoxide.

6. The cosmetic gel composition of claim 1 , wherein said permeation enhancer comprises an alcohol.

7. The cosmetic gel composition of claim 6 , wherein said permeation enhancer comprises propylene glycol.

8. The cosmetic gel composition of claim 1 , wherein said cosmetic gel composition is a controlled-release composition.

9. The cosmetic gel composition of claim 5 , wherein the permeation enhancer increases skin permeation of the alpha-adrenergic agent or the salt thereof by about 0.5 mm or more relative to a composition without the permeation enhancer.

10. The cosmetic gel composition of claim 5 , wherein the permeation enhancer increases skin permeation of the alpha-adrenergic agent or the salt thereof by about 2-fold or greater relative to a composition without the permeation enhancer.

11. The cosmetic gel composition of claim 10 , wherein the permeation enhancer increases skin permeation of oxymetazoline or a salt thereof by about 3-fold or greater relative to a composition without the permeation enhancer.

12. The cosmetic gel composition of claim 1 , further comprising one or more dermatologically acceptable carriers.

13. The cosmetic gel composition of claim 1 , wherein the one or more dermatologically acceptable carriers are individually selected from buffers, preservatives, gelling agents, rheological modifiers and stabilizers, moisturizers, and humectants.

14. The cosmetic gel composition of claim 1 , wherein the one or more cosmetic excipients are individually selected from sunscreens, fragrances, pigments and antioxidants.

15. A method of contacting Muller's muscle with an alpha-adrenergic agent, comprising applying a dose of the cosmetic gel of claim 1 to the exterior surface of the upper eyelid of a subject.

16. A method of permeating the septal fat pad with an alpha-adrenergic agent, comprising applying a dose of the cosmetic gel of claim 1 to the exterior surface of the upper eyelid of a subject.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2021
From: LITVACK, FRANK; HEMMATI, HOUMAN
To: LEVATION PHARMA LTD.
Reel/Frame 055705/0872 →
Continuity (4)
Division 16043725 · Jul 24, 2018
Continuation PCTUS2017015181 · Jan 26, 2017
Provisional Application 62287391 · Jan 26, 2016
Related Publication 20210259956A1 · Aug 26, 2021
Cited By (3)
US 12,357,561 US 12,605,363 US 12,648,930